ORLANDO — There is an urgent need for new therapies to treat relapsed or refractory peripheral T-cell lymphoma, but results of a phase 2 study suggest that monotherapy with the immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results